Lipid-lowering effects of zerumbone, a natural cyclic sesquiterpene of Zingiber zerumbet Smith, in high-fat diet-induced hyperlipidemic hamsters

Food and Chemical Toxicology

Volumn 69, Issue , 2014, Pages 132-139

  Tzeng, Thing Fong ^a   Lu, Hung Jen ^b   Liou, Shorong Shii ^c   Chang, Chia Ju ^c   Liu, I Min ^c  

^a Pao Chien Hospital   (Taiwan)

^b KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c TAJEN UNIVERSITY   (Taiwan)

Author keywords

High fat diet; Hyperlipidemic hamsters; Lipids metabolism; Zerumbone

Indexed keywords

ACYL COENZYME A OXIDASE; CARNITINE PALMITOYLTRANSFERASE; FATTY ACID SYNTHASE; FECES LIPID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALATE DEHYDROGENASE (DECARBOXYLATING); MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; STEROL REGULATORY ELEMENT BINDING PROTEIN; ZERUMBONE; LIPID; SESQUITERPENE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRIACYLGLYCEROL LIPASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG MECHANISM; DYSLIPIDEMIA; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; GENE EXPRESSION; HERBAL MEDICINE; HYPERLIPIDEMIA; LIPID DIET; LIPID METABOLISM; LIPOLYSIS; MALE; NONHUMAN; SYRIAN HAMSTER; UPREGULATION; ZINGIBER ZERUMBET; ADVERSE EFFECTS; ANIMAL; BLOOD; BODY WEIGHT; CHEMICALLY INDUCED; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; EATING; FECES; GENE EXPRESSION REGULATION; GENETICS; HYPERLIPIDEMIAS; LIVER; MESOCRICETUS; METABOLISM; PATHOLOGY; ZINGIBERACEAE;

ANIMALS; BODY WEIGHT; CARNITINE O-PALMITOYLTRANSFERASE; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; EATING; FECES; GENE EXPRESSION REGULATION; HYPERLIPIDEMIAS; LIPASE; LIPID METABOLISM; LIPIDS; LIPOLYSIS; LIVER; MALE; MESOCRICETUS; SESQUITERPENES; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; ZINGIBERACEAE;

EID: 84899793750     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2014.03.036     Document Type: Article

References (37)

1. Abbott R.D., Wilson P.W., Kannel W.B., Castelli W.P. High density lipoprotein-cholesterol, total cholesterol screening and myocardial infarction. The framingham study. Arterosclerosis 1988, 8:207-211.
2. Arsenault B.J., Kritikou E.A., Tardif J.C. Regression of atherosclerosis. Curr. Cardiol. Rep. 2012, 14:443-449.
3. Bartlett K., Eaton S. Mitochondrial beta-oxidation. Eur. J. Biochem. 2004, 271:462-469.
4. Braissant O., Foufelle F., Scotto C., Dauca M., Wahli W. Differential expression of peroxisome proliferator-activated receptors: tissue distribution of PPAR-α, -β and -γ in the adult rat. Endocrinology 1996, 137:354-366.
5. Chang C.J., Tzeng T.F., Liou S.S., Chang Y.S., Liu I.M. Regulation of lipid disorders by ethanol extracts from Zingiber zerumbet in high-fat diet-induced rats. Food Chem. 2012, 132:460-467.
6. Chang C.J., Liou S.S., Tzeng T.F., Liu I.M. The ethanol extract of Zingiber zerumbet Smith attenuates non-alcoholic fatty liver disease in hamsters fed on high-fat diet. Food Chem. Toxicol. 2014, 65:33-42.
7. Drexel H. Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients?. Fundam. Clin. Pharmacol. 2009, 23:687-692.
8. Eberlé D., Hegarty B., Bossard P., Ferré P., Fufelle F. SREBP transcription factors: master regulators of lipid homeostasis. Biochimie 2004, 86:839-848.
9. Folch J., Lees M., Sloane-Stanley G.H. A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem. 1957, 226:497-506.
10. Frazier-Wood A.C., Ordovas J.M., Straka R.J., Hixson J.E., Borecki I.B., Tiwari H.K., Arnett D.K. The PPAR alpha gene is associated with triglyceride, low-density cholesterol and inflammation marker response to fenofibrate intervention: the GOLDN study. Pharm. J. 2013, 13:312-317.
11. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. Clin. Chem. 1972, 18:499-502.
12. Gargouri Y., Ransac S., Verger R. Covalent inhibition of digestive lipases: an in vitro study. Biochim. Biophys. Acta 1997, 1344:6-37.
13. Giboney P.T. Mildly elevated liver transaminase levels in the asymptomatic patient. Am. Fam. Physician 2005, 71:1105-1110.
14. Horton J.D. Sterol regulatory element-binding proteins: transcriptional activators of lipid synthesis. Biochem. Soc. Trans. 2002, 30:1091-1095.
15. Huang G.C., Chien T.Y., Chen L.G., Wang C.C. Antitumor effects of zerumbone from Zingiber zerumbet in P-388D1 cells in vitro and in vivo. Planta Med. 2005, 71:219-224.
16. Ito M.K. Dyslipidemia: management using optimal lipid-lowering therapy. Ann. Pharmacother. 2012, 46:1368-1381.
17. Jacobson T.A. Myopathy with statin-fibrate combination therapy: clinical considerations. Nat. Rev. Endocrinol. 2009, 5:507-518.
18. Katsiki N., Nikolic D., Montalto G., Banach M., Mikhailidis D.P., Rizzo M. The role of fibrate treatment in dyslipidemia: an overview. Curr. Pharm. Des. 2013, 19:3124-3131.
19. Kirana C., McIntosh G.H., Record I.R., Jones G.P. Antitumor activity of extract of Zingiber aromaticum and its bioactive sesquiterpenoid zerumbone. Nutr. Cancer 2003, 45:218-225.
20. Kitayama T. Attractive reactivity of a natural product, zerumbone. Biosci. Biotechnol. Biochem. 2011, 75:199-207.
21. Kraja A.T., Province M.A., Straka R.J., Ordovas J.M., Borecki I.B., Arnett D.K. Fenofibrate and metabolic syndrome. Endocr. Metab. Immune Disord. Drug Targets. 2010, 10:138-148.
22. Kris-Etherton P.M., Dietschy J. Design criteria for studies examining individual fatty acid effects on cardiovascular disease risk factors: human and animal studies. Am. J. Clin. Nutr. 1997, 65:1590S-1596S.
23. Liu Z.L., Liu J.P., Zhang A.L., Wu Q., Ruan Y., Lewith G., Visconte D. Chinese herbal medicines for hypercholesterolemia. Cochrane Database Syst. Rev. 2011, 6:CD008305.
24. -δδCT method. Methods 2001, 25:402-408.
25. Nguyen P., Leray V., Diez M., Serisier S., Le Bloc'h J., Siliart B., Dumon H. Liver lipid metabolism. J. Anim. Physiol. Anim. Nutr. (Berl) 2008, 92:272-283.
26. Poirier Y., Antonenkov V.D., Glumoff T., Hiltunen J.K. Peroxisomal beta-oxidation-a metabolic pathway with multiple functions. Biochim. Biophys. Acta 2006, 1763:1413-1426.
27. Rao M.S., Reddy J.K. Peroxisomal β-oxidation and steatohepatitis. Semin. Liver Dis. 2001, 21:43-55.
28. Rector R.S., Payne R.M., Ibdah J.A. Mitochondrial trifunctional protein defects: clinical implications and therapeutic approaches. Adv. Drug Deliv. Rev. 2008, 60:1488-1496.
29. Reddy J.K., Hashimoto T. Peroxisomal beta-oxidation and peroxisome proliferator activated receptor alpha: an adaptive metabolic system. Annu. Rev. Nutr. 2001, 21:193-230.
30. Roh C., Jung U. Screening of crude plant extracts with anti-obesity. Int. J. Mol. Sci. 2012, 13:1710-1719.
31. Sato R. Sterol metabolism and SREBP activation. Arch. Biochem. Biophys. 2010, 501:177-181.
32. Shanmugasundaram K.R., Visvanathan A., Dhandapani K., Srinivasan N., Rasappan P., Gilbert R., Alladi S., Kancharla S., Vasanthi N. Effect of high-fat diet on cholesterol distribution in plasma lipoproteins, cholesterol esterifying activity in leucocytes, and erythrocyte membrane components studied: importance of body weight. Am. J. Clin. Nutr. 1986, 44:805-815.
33. Shimomura I., Shimano H., Korn B.S., Bashmakov Y., Horton J.D. Nuclear sterol regulatory element binding proteins activate genes responsible for entire program of unsaturated fatty acid biosynthesis in transgenic mouse liver. J. Biol. Chem. 1998, 273:35299-35306.
34. Sundaram M., Yao Z. Intrahepatic role of exchangeable apolipoproteins in lipoprotein assembly and secretion. Arterioscler. Thromb. Vasc. Biol. 2012, 32:1073-1078.
35. Szabolcs A., Tiszlavicz L., Kaszaki J., Pósa A., Berkó A., Varga I.S., Boros I., Szüts V., Lonovics J., Takács T. Zerumbone exerts a beneficial effect on inflammatory parameters of cholecystokinin octapeptide-induced experimental pancreatitis but fails to improve histology. Pancreas 2007, 35:249-255.
36. Wang P.R., Guo Q., Ippolito M., Wu M., Milot D., Ventre J., Doebber T., Wright S.D., Chao Y.S. High fat fed hamster, a unique animal model for treatment of diabetic dyslipidemia with peroxisome proliferator activated receptor alpha selective agonists. Eur. J. Pharmacol. 2001, 427:285-293.
37. Yob N.J., Jofrry S.M., Affandi M.M., Teh L.K., Salleh M.Z., Zakaria Z.A. Zingiber zerumbet (L) Smith: a review of its ethnomedicinal, chemical, and pharmacological uses. Evid. based complement. Alternat. Med. 2011, 2011:543216.